Correlation Engine 2.0
Clear Search sequence regions


  • claudin 1 (1)
  • e cadherin (1)
  • humans (1)
  • IL 6 (1)
  • infants (1)
  • JAK2 (1)
  • JMJD3 (9)
  • kdm6b protein, human (1)
  • mice (4)
  • necroptosis (1)
  • neonates (1)
  • NF kappa B (2)
  • NF κB (1)
  • occludin (1)
  • pathogenesis (1)
  • patients (2)
  • protein human (1)
  • sepsis (2)
  • STAT3 (1)
  • tnf α (1)
  • Sizes of these terms reflect their relevance to your search.

    Necrotizing enterocolitis (NEC), an acute intestinal inflammatory disease of premature infants, is one of the leading causes of death in neonates. Effective measures for clinical treatment are limited and there is a pressing need in searching for new therapeutic strategies. Jumonji domain-containing protein D3 (JMJD3), a histone H3 lysine 27 (H3K27) demethylase plays a proinflammatory role in sepsis and neuroinflammation. However, whether JMJD3 is involved in the pathogenesis of NEC has not been elucidated. Here we report that overexpressed JMJD3 was revealed in the intestine of NEC patients by bioinformatic analysis. Moreover, upregulated JMJD3 and suppressed H3K27me3 were detected in both NEC patients and neonatal mice subjected to experimental NEC. Importantly, administration of GSK-J4, a specific JMJD3 inhibitor, rescued neonatal mice from NEC-associated lethality by suppressing proinflammatory response with attenuated IL-6, TNF-α, and MCP-1 levels and ameliorating intestinal injury with reversed claudin-1, occludin, and E-cadherin expression. Remarkably, administration of GSK-J4 attenuated intestinal injury by inhibiting activation of intestinal necroptosis in NEC mice. Administration of GSK-J4 regulated intestinal inflammation via NF-κB and JAK2/STAT3 pathway. These results indicate that JMJD3 is involved in the development of NEC and inhibition of JMJD3 overexpression by mean of GSK-J4 could be a potential therapeutic approach in the prevention and treatment of NEC. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

    Citation

    Shurong Ma, Lingqi Xu, Lulu Chen, Xu Sun, Fangjie Hu, Yuan Gong, Randong Yang, Jing Li, Qian Wang, Shungen Huang, Huiting Zhou, Jian Wang. Novel pharmacological inhibition of JMJD3 improves necrotizing enterocolitis by attenuating the inflammatory response and ameliorating intestinal injury. Biochemical pharmacology. 2022 Sep;203:115165

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35803318

    View Full Text